TD Cowen Initiates Coverage on Vor Biopharma (NASDAQ:VOR)

Stock analysts at TD Cowen assumed coverage on shares of Vor Biopharma (NASDAQ:VOR) in a research note issued on Wednesday, Marketbeat.com reports. The firm set a “buy” rating on the stock.

A number of other analysts have also recently weighed in on the stock. Zacks Research upgraded shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a report on Tuesday, November 11th. Stifel Nicolaus upgraded shares of Vor Biopharma from a “hold” rating to a “buy” rating and set a $55.00 target price for the company in a research note on Wednesday, September 24th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, October 8th. JPMorgan Chase & Co. started coverage on Vor Biopharma in a report on Tuesday, December 9th. They set an “overweight” rating and a $43.00 price objective for the company. Finally, HC Wainwright dropped their target price on Vor Biopharma from $55.00 to $32.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, five have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Vor Biopharma presently has an average rating of “Moderate Buy” and a consensus price target of $68.86.

Vor Biopharma Price Performance

Shares of NASDAQ VOR opened at $12.80 on Wednesday. Vor Biopharma has a 12-month low of $2.62 and a 12-month high of $65.80. The firm’s fifty day moving average is $16.87. The company has a market cap of $133.25 million, a PE ratio of -0.03 and a beta of 2.08.

Insiders Place Their Bets

In related news, major shareholder Reprogrammed Interchange Llc sold 11,616 shares of the company’s stock in a transaction on Monday, October 20th. The stock was sold at an average price of $30.05, for a total value of $349,060.80. Following the transaction, the insider directly owned 1,167,109 shares of the company’s stock, valued at $35,071,625.45. This represents a 0.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. sold 24,579 shares of Vor Biopharma stock in a transaction dated Thursday, October 30th. The stock was sold at an average price of $25.12, for a total value of $617,424.48. Following the sale, the director directly owned 779,652 shares of the company’s stock, valued at approximately $19,584,858.24. This represents a 3.06% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 1,674,800 shares of company stock worth $49,516,960 over the last three months. Corporate insiders own 0.45% of the company’s stock.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently modified their holdings of VOR. Bank of America Corp DE boosted its position in Vor Biopharma by 679.3% during the third quarter. Bank of America Corp DE now owns 4,754 shares of the company’s stock worth $232,000 after purchasing an additional 4,144 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Vor Biopharma during the 3rd quarter worth approximately $230,000. BNP Paribas Financial Markets raised its stake in shares of Vor Biopharma by 497.3% during the 3rd quarter. BNP Paribas Financial Markets now owns 6,075 shares of the company’s stock worth $296,000 after buying an additional 5,058 shares during the period. Bridgeway Capital Management LLC purchased a new position in shares of Vor Biopharma during the 3rd quarter valued at approximately $304,000. Finally, Polymer Capital Management HK LTD acquired a new stake in Vor Biopharma in the 3rd quarter valued at $1,035,000. Hedge funds and other institutional investors own 97.29% of the company’s stock.

About Vor Biopharma

Vor Biopharma, Inc, a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company’s VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells.